Target-specific immunoPET Imaging of Breast Cancer
This study tests new imaging methods called PET/CT scans that use special markers to find breast cancer cells in the body. These markers target specific proteins (Trop2 and HER2) that are commonly found on breast cancer cells, potentially helping doctors see tumors more clearly.
Key Objective:This trial is testing whether targeted PET/CT imaging can more accurately detect and evaluate breast cancer compared to standard imaging methods.
Who to Consider:Women diagnosed with breast cancer or those at high risk for breast cancer who are interested in exploring advanced imaging techniques may want to consider this study.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-75 years old and of female gender； 2. Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging; 3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. Exclusion Criteria: 1. Pregnancy； 2. Severe hepatic and renal insufficiency; 3. History of serious surgery in the last month; 4. Allergic to antibody or single-domain antibody radiopharmaceuticals.